SPDR S&P Pharmaceuticals ETF

XPH

Market cap $168M

Overview Fund Activity

45.99 USD

-0.01

0.02%

At close Updated Sep 16, 4:00 PM EDT

1 day

-0.02%

5 days

-3.36%

1 month

-0.13%

3 months

10.42%

6 months

5.22%

Year to date

7.86%

1 year

3.86%

5 years

1.55%

10 years

-20.43%

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

3.67% more ownership

Funds ownership: 75.09% [Q1] → 78.75% (+3.67%) [Q2]

4% less funds holding

Funds holding: 68 [Q1] → 65 (-3) [Q2]

9% less capital invested

Capital invested by funds: $128M [Q1] → $117M (-$11.5M) [Q2]

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

30% less call options, than puts

Call options by funds: $783K | Put options by funds: $1.12M

32% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 25

See Fund Rankings

Financial journalist opinion

Schaeffers Research

35 ETFs to Watch After the S&P 500's Most Recent Surge

Over the last 100 trading days, or roughly five months, the S&P 500 Index (SPX) has surged more than 25%.

35 ETFs to Watch After the S&P 500's Most Recent Surge

Trump hints at higher semiconductor tariffs. Companies could dodge them by doing this.

Trump suggested steep chip-industry tariffs are coming, but there could be breaks for companies that invest in the U.S. Specifics are still sparse.

Trump hints at higher semiconductor tariffs. Companies could dodge them by doing this.

US FDA announces new program to boost domestic drug manufacturing

The U.S. Food and Drug Administration on Thursday announced a new program to strengthen the domestic pharmaceutical supply chain, by facilitating construction of manufacturing sites in the United States.

US FDA announces new program to boost domestic drug manufacturing

Trump threatens drugmakers with 250% tariffs. Here's when higher levies could come.

The latest level of tariffs on the pharmaceutical industry is the highest yet from the president.

Trump threatens drugmakers with 250% tariffs. Here's when higher levies could come.

XPH: Healthcare Dashboard For July

This article provides a top-down view of the healthcare sector based on valuation and quality metrics. Healthcare providers are the most undervalued subsector, while pharma/biotech has the best quality score. XPH ETF offers equal-weighted exposure to pharmaceutical companies, with lackluster results for a decade.

XPH: Healthcare Dashboard For July

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Zacks Investment Research

ETFs on the Move Post U.S.-China Trade Deal

Let's delve into the ETF world following the 90-day U.S.-China trade deal.

ETFs on the Move Post U.S.-China Trade Deal

Zacks Investment Research

A Look at Pharma ETFs After Strong Q1 Earnings

Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Strong Q1 Earnings

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volatility.

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks

CNBC Television

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

See News Rankings

Charts implemented using Lightweight Charts™